An Adaptive Study of the Pharmacokinetics of Favipiravir in Patients With Severe Influenza
Phase of Trial: Phase II
Latest Information Update: 16 May 2019
Price : $35 *
At a glance
- Drugs Favipiravir (Primary) ; Oseltamivir
- Indications Influenza virus infections
- Focus Pharmacokinetics
- 14 May 2019 Status changed from active, no longer recruiting to completed.
- 10 Jan 2019 Planned End Date changed from 10 Feb 2019 to 10 Mar 2019.
- 10 Jan 2019 Planned primary completion date changed from 10 Dec 2018 to 20 Jan 2019.